Compositions useful in treating brain-related diseases or disorders and methods using same

Patent metadata

Field	Value
Publication number	US-9616065-B2
Application number	US-201414784536-A
Country	US
Kind code	B2
Filing date	Apr 16, 2014
Priority date	Apr 16, 2013
Publication date	Apr 11, 2017
Grant date	Apr 11, 2017

Abstract

The present invention provides compounds useful for treating or preventing a brain-related disease or disorder. The present invention further provides a method of treating or preventing a brain-related disease or disorder in a patient, the method comprising administering to the patient a pharmaceutical composition comprising at least one compound of the invention. The present invention further provides a method of modulating the activity of a monoamine transporter.

First claim

What is claimed is:

1. A compound of Formula (III):

wherein in Formula (III),
ring A is triazinoindolyl optionally substituted with 1-4 R 1 groups;
each occurrence of R 1 is independently selected from the group consisting of —C 1 -C 6 alkyl, —C 1 -C 6 fluoroalkyl, —C 1 -C 6 heteroalkyl, F, Cl, Br, and I;
R 2 is selected from the group consisting of H and C 1 -C 6 alkyl;
R 3 is selected from the group consisting of —S(═O) 2 R 4 and —C(═O)R 4 ;
phenyl which is optionally substituted with one or two substituents selected from the group consisting of C 1 -C 6 alkyl, OH, C 1 -C 6 alkoxy, halo, amino, acetamido and nitro; and
x is an integer from 0-4;

a salt or solvate thereof, and any combinations thereof.

2. The compound of claim 1 ,
which is N-[4-({2-[(8-ethyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)sulfanyl]ethyl}sulfamoyl) phenyl]acetamide, a salt thereof, a solvate thereof, and any combinations thereof.

3. A pharmaceutically acceptable composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

4. The compound of claim 1 , wherein ring A is 8-ethyl-5H[1,2,4]triazine[5,6-b]indol3-yl.

5. The compound of claim 1 , wherein each occurrence of R 1 is independently selected from the group consisting of —C 1 -C 6 alkyl, —C 1 -C 6 fluoroalkyl and —C 1 -C 6 heteroalkyl.

6. The compound of claim 5 , wherein each occurrence of R 1 is independently —C 1 -C 6 alkyl.

7. The compound of claim 1 , wherein R 2 is H.

8. The compound of claim 1 , wherein R 3 is —S(═O) 2 R 4 .

9. The compound of claim 1 , wherein R 4 is 4-acetamidophenyl.

Assignees

• Univ Drexel

Inventors

• Kortagere Sandhya
• Mortensen Ole Valente
• Mortensen Andreia C K
• Salvino Joseph M

Classifications

• A61K31/53 Primary

  having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495}) · CPC title

• A61K31/635

  having a heterocyclic ring, e.g. sulfadiazine · CPC title

• C07D487/04 Primary

  Ortho-condensed systems · CPC title

• A61K31/4709

  Non-condensed quinolines and containing further heterocyclic rings · CPC title

• A61K31/4184

  condensed with carbocyclic rings, e.g. benzimidazoles · CPC title